Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln

Reuters11-12

Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln

Overview

PolyPid reports Q3 net loss of $7.5 mln, down from $7.8 mln last year
Company advances regulatory strategy with pre-NDA meeting scheduled for December
PolyPid progresses in U.S. partnership talks post positive Phase 3 trial results

Outlook

PolyPid plans NDA submission for D-PLEX₁₀₀ in early 2026
Company advancing U.S. partnership discussions for D-PLEX₁₀₀
PolyPid expects cash balance to fund operations into 2026

Result Drivers

R&D - The increase in R&D expenses was primarily due to activities related to the completion of the SHIELD II Phase 3 trial and preparation for regulatory submissions

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		$0.37
Q3 Net Income		$7.45 mln
Q3 Operating Income		$7.46 mln
Q3 Pretax Profit		$7.43 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 71.1% above its November 11 closing price of $3.76

Press Release: ID:nGNX9rSTFN

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582376981?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582376981","market":"fut","top_or_hot":-1,"title":"Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln</title></head><body><p><span>Overview</span></p><ul><li><p>PolyPid reports Q3 net loss of $7.5 mln, down from $7.8 mln last year</p></li><li><p>Company advances regulatory strategy with pre-NDA meeting scheduled for December</p></li><li><p>PolyPid progresses in U.S. partnership talks post positive Phase 3 trial results</p></li></ul><p><span>Outlook</span></p><ul><li><p>PolyPid plans NDA submission for D-PLEX₁₀₀ in early 2026</p></li><li><p>Company advancing U.S. partnership discussions for D-PLEX₁₀₀</p></li><li><p>PolyPid expects cash balance to fund operations into 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D - The increase in R&amp;D expenses was primarily due to activities related to the completion of the SHIELD II Phase 3 trial and preparation for regulatory submissions</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>$0.37</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>$7.45 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>$7.46 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>$7.43 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 71.1% above its November 11 closing price of $3.76</p></li></ul><p>Press Release: <span>ID:nGNX9rSTFN</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharma firm PolyPid's Q3 net loss narrows to $7.5 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln</title></head><body><p><span>Overview</span></p><ul><li><p>PolyPid reports Q3 net loss of $7.5 mln, down from $7.8 mln last year</p></li><li><p>Company advances regulatory strategy with pre-NDA meeting scheduled for December</p></li><li><p>PolyPid progresses in U.S. partnership talks post positive Phase 3 trial results</p></li></ul><p><span>Outlook</span></p><ul><li><p>PolyPid plans NDA submission for D-PLEX₁₀₀ in early 2026</p></li><li><p>Company advancing U.S. partnership discussions for D-PLEX₁₀₀</p></li><li><p>PolyPid expects cash balance to fund operations into 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D - The increase in R&amp;D expenses was primarily due to activities related to the completion of the SHIELD II Phase 3 trial and preparation for regulatory submissions</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>$0.37</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>$7.45 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>$7.46 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>$7.43 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 71.1% above its November 11 closing price of $3.76</p></li></ul><p>Press Release: <span>ID:nGNX9rSTFN</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PYPD","symbol_name":"PolyPid Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0ET:1","article_id":"2582376981","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582376981","pubTimestamp":1762951099,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mlnOverviewPolyPid reports Q3 net loss of $7.5 mln, down from $7.8 mln last yearCompany advances regulatory strategy with pre-NDA meeting scheduled","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PYPD":"PolyPid Ltd.","BK4007":"制药"},"translate_title":"生物制药公司PolyPid第三季度净亏损收窄至750万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYPD":0.9},"content_text":"Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mlnOverviewPolyPid reports Q3 net loss of $7.5 mln, down from $7.8 mln last yearCompany advances regulatory strategy with pre-NDA meeting scheduled for DecemberPolyPid progresses in U.S. partnership talks post positive Phase 3 trial resultsOutlookPolyPid plans NDA submission for D-PLEX₁₀₀ in early 2026Company advancing U.S. partnership discussions for D-PLEX₁₀₀PolyPid expects cash balance to fund operations into 2026Result DriversR&D - The increase in R&D expenses was primarily due to activities related to the completion of the SHIELD II Phase 3 trial and preparation for regulatory submissionsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS$0.37Q3 Net Income$7.45 mlnQ3 Operating Income$7.46 mlnQ3 Pretax Profit$7.43 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 71.1% above its November 11 closing price of $3.76Press Release: ID:nGNX9rSTFNFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582376981","isCrawlerRequest":true}